Genzyme's Pipeline Outlook

	Research	Preclinical	Phase 1	Phase 2	Phase 3	Postmarketing Studies
GENETIC DISEASES
Fabrazyme Fabry disease
Myozyme Pompe disease
Genz-112638 oral therapy Gaucher disease
Ataluren Duchenne and Becker muscular dystrophy
Acid Sphingomyelinase Niemann-Pick Type B
Gene Therapy Parkinson's disease
Neo-GAA next generation Pompe disease treatment
CARDIOMETABOLIC / RENAL
Cholestagel familial hypercholesterolemia
Renvela chronic kidney disease not on dialysis
Mipomersen familial hypercholesterolemia
Mipomersen severe hypercholesterolemia
TSH nontoxic multinodular goiter
GC1008 kidney sclerosis
HEMATOLOGIC ONCOLOGY
Campath combination CLL
Prochymal graft vs. host disease
Clolar combination adult rel/ref AML
Clolar adult AML
Thymoglobulin myelodysplastic syndromes
Mozobil tumor sensitization
Clolar combination pediatric rel/ref ALL and AML
Clolar oral myelodysplastic syndromes
GC1008 solid tumors
TRANSPLANT / IMMUNE DISEASES
Alemtuzumab multiple sclerosis
Prochymal Crohn's disease
Thymoglobulin liver transplant
Hectorol psoriasis
GC1008 pulmonary fibrosis
Mozobil solid organ transplant/autoimmune disease
BIOSURGERY
Synvisc-One osteoarthritis pain relief
Hylastan (EU) new formulation
SepraSpray (EU) post-surgical adhesions
MACI articular cartilage defects
Chondrogen osteoarthritis
SepraSpray (US) post-surgical adhesions
Gen-S osteoarthritis pain relief